CLARITIN ALLERGY + SINUS TABLET (IMMEDIATE AND EXTENDED RELEASE)

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

PSEUDOEPHEDRINE SULFATE; LORATADINE

제공처:

BAYER INC

ATC 코드:

R01BA52

INN (International Name):

PSEUDOEPHEDRINE, COMBINATIONS

복용량:

120MG; 5MG

약제 형태:

TABLET (IMMEDIATE AND EXTENDED RELEASE)

구성:

PSEUDOEPHEDRINE SULFATE 120MG; LORATADINE 5MG

관리 경로:

ORAL

패키지 단위:

10/20/30

처방전 유형:

OTC

치료 영역:

SECOND GENERATION ANTIHISTAMINES

제품 요약:

Active ingredient group (AIG) number: 0245861002; AHFS:

승인 상태:

APPROVED

승인 날짜:

2014-12-08

제품 특성 요약

_<_
_CLARITIN_
_®_
_ ALLERGY + SINUS> _
_ _
_ _
_ _
_Page 1 of 33_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
CLARITIN® ALLERGY + SINUS
Loratadine and Pseudoephedrine Sulfate
Modified-Release Tablets, Professed Standard
5 mg Loratadine and 120 mg Pseudoephedrine Sulfate; Oral
CLARITIN® ALLERGY + SINUS EXTRA STRENGTH
Loratadine and Pseudoephedrine Sulfate
Modified-Release Tablets, Professed Standard
10 mg Loratadine and 240 mg Pseudoephedrine Sulfate; Oral
Histamine H1 receptor antagonist/Sympathomimetic amine
Bayer Inc.
2920 Matheson Blvd. E
Mississauga, ON
L4W 5R6
Date of Initial Authorization:
Claritin® Allergy + Sinus:
2-Mar-1993
Claritin® Allergy +Sinus Extra
Strength:
4-Dec-2004
Date of Revision:
NOV-01-2022
Submission Control Number: 265671
® TM see www.bayer.ca/tm-mc
_ _
_< CLARITIN_
_®_
_ ALLERGY + SINUS> _
_ _
_ _
_Page 2 of 33 _
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
TABLE OF CONTENTS
...........................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................. 4
1.
INDICATIONS................................................................................................................
4
1.1
Pediatrics
..................................................................................................................
4
1.2
Geriatrics...................................................................................................................
4
2.
CONTRAINDICATIONS
..................................................................................................
4
4.
DOSAGE AND ADMI